Literature DB >> 15102347

Low-grade glioma: supratentorial astrocytoma, oligodendroglioma, and oligoastrocytoma in adults.

Lynn S Ashby1, William R Shapiro.   

Abstract

Low-grade glioma is not a single diagnosis but a category of biologically diverse neoplasms. They are indolent, progressive, and, following anaplastic transformation, invariably fatal. Neuro-oncologists have not established a treatment standard for these tumors. However, it is clear that "low-grade" is not synonymous with "benign," and treatment is required sometime in the course of the disease. Previously, achieving a consensus had been limited by a lack of class I evidence. Physicians treated patients based on retrospective series and personal experience. Currently, results from prospective clinical trials are becoming available. These studies have provided data that may serve as treatment guidelines. Additional results regarding the identification of prognostic variables have raised more questions to be answered. Attention is now directed to the importance of translational research to better define these neoplasms. In the future, it will be necessary to distinguish among low-grade gliomas and identify therapies that may differ between them.

Entities:  

Mesh:

Year:  2004        PMID: 15102347     DOI: 10.1007/s11910-004-0041-5

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  47 in total

1.  Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.

Authors:  J S Smith; A Perry; T J Borell; H K Lee; J O'Fallon; S M Hosek; D Kimmel; A Yates; P C Burger; B W Scheithauer; R B Jenkins
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

2.  Proliferating cell nuclear antigen and Ki-67 immunohistochemistry of oligodendrogliomas with special reference to prognosis.

Authors:  S Heegaard; H M Sommer; H Broholm; O Broendstrup
Journal:  Cancer       Date:  1995-11-15       Impact factor: 6.860

Review 3.  Oligodendroglioma: pathology and molecular biology.

Authors:  Herbert H Engelhard; Ana Stelea; Elizabeth J Cochran
Journal:  Surg Neurol       Date:  2002-08

4.  Ki-67: a prognostic factor for low-grade glioma?

Authors:  Barbara J Fisher; Elitza Naumova; Christopher C Leighton; George N Naumov; Nancy Kerklviet; David Fortin; David R Macdonald; J Gregory Cairncross; Glenn S Bauman; Larry Stitt
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-03-15       Impact factor: 7.038

5.  Absence of contrast enhancement on CT brain scans of patients with supratentorial malignant gliomas.

Authors:  M C Chamberlain; J A Murovic; V A Levin
Journal:  Neurology       Date:  1988-09       Impact factor: 9.910

Review 6.  Chemotherapy of low-grade gliomas.

Authors:  G J Lesser
Journal:  Semin Radiat Oncol       Date:  2001-04       Impact factor: 5.934

7.  The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas.

Authors:  M S Berger; A V Deliganis; J Dobbins; G E Keles
Journal:  Cancer       Date:  1994-09-15       Impact factor: 6.860

8.  Grading of astrocytomas. A simple and reproducible method.

Authors:  C Daumas-Duport; B Scheithauer; J O'Fallon; P Kelly
Journal:  Cancer       Date:  1988-11-15       Impact factor: 6.860

9.  Low-grade oligodendroglioma responds to chemotherapy.

Authors:  W P Mason; G S Krol; L M DeAngelis
Journal:  Neurology       Date:  1996-01       Impact factor: 9.910

Review 10.  Pathology of low-grade gliomas: an update of emerging concepts.

Authors:  Arie Perry
Journal:  Neuro Oncol       Date:  2003-07       Impact factor: 12.300

View more
  7 in total

1.  Diagnosis of malignant glioma: role of neuropathology.

Authors:  Daniel J Brat; Richard A Prayson; Timothy C Ryken; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2008-08-20       Impact factor: 4.130

2.  Integration of epidemiology, immunobiology, and translational research for brain tumors.

Authors:  Hideho Okada; Michael E Scheurer; Saumendra N Sarkar; Melissa L Bondy
Journal:  Ann N Y Acad Sci       Date:  2013-05       Impact factor: 5.691

3.  Preoperative estimation of residual volume for WHO grade II glioma resected with intraoperative functional mapping.

Authors:  Emmanuel Mandonnet; Saad Jbabdi; Luc Taillandier; Damien Galanaud; Habib Benali; Laurent Capelle; Hugues Duffau
Journal:  Neuro Oncol       Date:  2006-10-03       Impact factor: 12.300

Review 4.  Assessment of therapeutic response and treatment planning for brain tumors using metabolic and physiological MRI.

Authors:  Sarah J Nelson
Journal:  NMR Biomed       Date:  2011-04-27       Impact factor: 4.044

5.  Subtelomeric analysis of pediatric astrocytoma: subchromosomal instability is a distinctive feature of pleomorphic xanthoastrocytoma.

Authors:  Elena Grau; J Balaguer; A Canete; F Martinez; C Orellana; S Oltra; M Hernandez; V Castel
Journal:  J Neurooncol       Date:  2008-12-20       Impact factor: 4.130

Review 6.  Immunotherapeutic approaches for glioma.

Authors:  Hideho Okada; Gary Kohanbash; Xinmei Zhu; Edward R Kastenhuber; Aki Hoji; Ryo Ueda; Mitsugu Fujita
Journal:  Crit Rev Immunol       Date:  2009       Impact factor: 2.214

7.  Cyclophilin A contributes to shikonin-induced glioma cell necroptosis and promotion of chromatinolysis.

Authors:  Xinyu Wang; Liwen Fan; Xuanzhong Wang; Tianfei Luo; Linlin Liu
Journal:  Sci Rep       Date:  2022-08-29       Impact factor: 4.996

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.